NEW YORK — Results of the KEYNOTE-189 trial dramatically altered initial treatment for patients with advanced-stage non-small cell lung cancer whose tumors do not harbor targetable alterations, according to a presenter at HemOnc Today New York.
However, no data are available to guide subsequent treatment decisions for later-line therapy, Benjamin Levy, MD, associate professor of oncology at Johns Hopkins University and clinical director of Sidney Kimmel Cancer Center at Sibley Memorial Hospital, said during his presentation.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.